{"entity":{"id":"mavrostobart","kind":"drug","name":"Mavrostobart","aka":["Mavrostobart (PT199)"],"tldr":"Mavrostobart is an experimental monoclonal antibody from Phanes Therapeutics in phase 2 trials for non-small-cell lung cancer and pancreatic ductal adenocarcinoma, aimed at CD73 / adenosine axis.","summary":"Mavrostobart (PT199) is a monoclonal antibody developed by Phanes Therapeutics. Its target is CD73 / adenosine axis. ClinicalTrials.gov describes the intervention as: Mavrostobart (PT199) is an anti-CD73 mAb with a differentiated mechanism of action. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer and pancreatic ductal adenocarcinoma. The largest, NCT05431270, plans to enrol 40 participants with primary completion expected 2027-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Mavrostobart","url":"https://clinicaltrials.gov/search?intr=PT199"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","pancreatic"],"sections":[],"technologies":[],"targets":["cd73-adenosine"],"drugs":[],"companies":["phanes-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05431270"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"PT199","modality":"monoclonal antibody","mechanism":"Monoclonal antibody directed at CD73 / adenosine axis, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/mavrostobart/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"target":[{"id":"cd73-adenosine","kind":"target","name":"CD73 / adenosine axis","route":"/targets/cd73-adenosine/"}],"company":[{"id":"phanes-therapeutics","kind":"company","name":"Phanes Therapeutics","route":"/companies/phanes-therapeutics/"}],"trial":[{"id":"nct05431270","kind":"trial","name":"Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy","route":"/trials/nct05431270/"}]}}